Survey: U.S.-China Trade War Has Firms Thinking About Leaving Both Countries

UPI International Top News |

The trade war between the United States and China has caused other companies to consider moving their operations out of both countries, new research showed Monday.

The research, conducted by the American Chamber of Commerce in South China, said 72 percent of 219 firms questioned said they were considering moving out of China -- while 77 percent said they were thinking about moving out of the United States.

Almost 50 percent of the companies are located in the United States, one-third are in mainland China and the rest are in other nations. The survey said about 95 percent of the companies have operations in China.

"It's reasonable and practical for them to relocate factories to other countries which will have stable and normal trading relations in the near future," Zhou Hao, a senior economist at Commerzbank in Singapore, told the South China Morning Post.

"What worries me the most is not so much the immediate impact, but the potential long-term loss of access by Chinese companies to the U.S. market and, as a result, American companies' access to a market that will eventually have five times as many consumers as the U.S.," chamber President Harley Seyedin said in a statement.

"The study, representing the factual points of view of participating companies from countries spanning the globe, will cause the leaders from both sides of the equation to pause and rethink their strategies."

The chamber said the study was done from , after the Trump administration levied an additional $200 billion in tariffs on Chinese products. That penalty followed Beijing imposing $60 billion in tariffs on U.S. imports.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Comments

Emerging Growth

IMV Inc.

Immunovaccine Inc is clinical stage biopharmaceutical company. The Company develops products based on its proprietary vaccine enhancement platform in T cell activating therapies for cancer.